Cannabis Ruderalis

Clinical data
ATC code
  • none
  • 2-cycloheptyl-5-(2-methyloctan-2-yl)benzene-1,3-diol
CAS Number
PubChem CID
Chemical and physical data
Molar mass332.528 g·mol−1
3D model (JSmol)
  • InChI=1S/C22H36O2/c1-4-5-6-11-14-22(2,3)18-15-19(23)21(20(24)16-18)17-12-9-7-8-10-13-17/h15-17,23-24H,4-14H2,1-3H3

O-1656 is a cannabinoid agonist which was invented by Billy R Martin and Raj K Razdan at Organix Inc in 2002. It is moderately selective for the CB2 receptor with a CB1 receptor affinity of 18 nM and a CB2 receptor affinity of 2 nM.[1][2][3] Since it has a cycloheptyl ring attached to the phenol core, it falls outside the definition of a "cyclohexylphenol derivative", but may still be controlled by generic legislation in some jurisdictions.

See also[edit]


  1. ^ WO application 03091189, Martin BR, Razdan RK, "Cannabinoids", published 6 November 2003, assigned to University of Virginia 
  2. ^ Wiley JL, Beletskaya ID, Ng EW, Dai Z, Crocker PJ, Mahadevan A, Razdan RK, Martin BR (May 2002). "Resorcinol derivatives: a novel template for the development of cannabinoid CB(1)/CB(2) and CB(2)-selective agonists". The Journal of Pharmacology and Experimental Therapeutics. 301 (2): 679–89. doi:10.1124/jpet.301.2.679. PMID 11961073. S2CID 12741224.
  3. ^ Adam J, Cowley PM, Kiyoi T, Morrison AJ, Mort CJ (2006). "Recent progress in cannabinoid research". Progress in Medicinal Chemistry. 44: 207–329. doi:10.1016/S0079-6468(05)44406-9. ISBN 9780444517371. PMID 16697899.

Leave a Reply